News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Centre for Neuro Skills Earns Accreditation in Applied Behavioral Analysis and Training at Three of its Locations

Centre for Neuro Skills

Centre for Neuro Skills (CNS), a leader in traumatic brain injury and stroke rehabilitation services, has been accredited by the Behavioral Health Center of Excellence (BHCOE) for demonstrating a commitment to the standards of excellence for applied behavior analysis services. The BHCOE Accreditation® distinguishes applied behavior analysis (ABA) therapy providers that demonstrate continuous improvement in applied behavior analysis and dedication. Three of CNS’ locations in Bakersfield and Los Angeles, California, and Irving, Texas have earned this accreditation and have been approved as training sites for behavior analysis students. Since 1980, Centre for Neuro Skills has treated thousands of people whose brain injury deficits include complex behavior challenges. Behavior analysts and therapists are trained in behavior skills, crisis prevention and management, and implementation of comprehensive, interdisciplinary rehabilitation programs. As an accredited training site, students and interns can learn from board-certified behavior analysts to help treat behavior problems. “We are thrilled that our behavior department and treatment program has been recognized as a standard of excellence,” said Chris Persel, Regional Director of Clinical Services and Director of Behavior Programming. “This accreditation opens up more opportunities for behavior analysis students and demonstrates the importance of providing behavioral analysis services to individuals facing a brain injury." *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

January 29, 2025 06:01 AM Pacific Standard Time

Image
Article thumbnail News Release

Shareholder Group, Detransitioner to Call Out Gender Ideology Harm at Visa, Inc. Annual Meeting on Tuesday

NLPC

National Legal and Policy Center, an investor in Visa, Inc., will present a shareholder proposal at the payment processor’s annual meeting on Tuesday, Jan. 28. The measure asks the company to investigate risks related to its discriminatory pay and benefits policies – specifically addressing where employees affected by gender-switching advocacy have been psychologically or medically harmed, without providing remedial care – and reporting to shareholders why such compensation gaps exist in the company’s policies. Speaking at Visa’s meeting in support of the proposal will be Claire Abernathy, a 20-year-old detransitioner whose therapy, medical and health insurance providers steered her into drastic body altering procedures when she questioned her gender starting at age 12. Ms. Abernathy will address the company’s board of directors and executive leadership, explaining her difficulties in finding medical care and insurance coverage to attempt to repair the damage done to her body. An excerpt from Abernathy’s planned remarks: By age 12 therapists affirmed my feelings about my body and false identity, and made my parents feel like abusive bigots for not immediately affirming me. The therapy was covered by my parents’ health insurance. Alleged medical professionals put me on a menstrual suppression drug, and at 14 I was put on testosterone and underwent a double mastectomy. It took only 8 months between getting referred for therapy and getting my breasts removed. That is an ideological agenda in search of victims, in the name of medicine, and it’s wrong. “By failing to include detransition care, companies like Visa perpetuate the neglect of a vulnerable population,” said Abernathy. “True equity in healthcare means acknowledging the full range of outcomes in gender transitioning treatments, and ensuring that all individuals have access to the care that they need.” In its shareholder proposal, NLPC itemizes numerous graphic, ghastly body-altering procedures that are drawn from Visa’s employee health insurance coverage through CIGNA, which also covers their minor dependents. Besides early-teen mastectomies like what Abernathy was pressured into, Visa also pays for procedures including penectomies, vaginectomies, orchiectomies, and salpingooophorectomies. “Rather than affirming and funding radical medical experiments on workers and their children – which sound more like something out of a horror movie than legitimate health care – Visa needs to just eliminate this coverage,” said Paul Chesser, director of the Corporate Integrity Project for NLPC. “With detransitioner lawsuits spreading across the country against medical providers and health facilities, corporations that sponsor this ‘care’ won’t be far behind in finding themselves in court.” As NLPC points out in its shareholder proposal, the Equal Employment Opportunity Commission considers failure to provide equivalent pay and benefits based on categories including “gender identity” and “sexual orientation” as discriminatory. Even the Securities and Exchange Commission agreed with NLPC that de-transitioning individuals fit under such classifications when considering unfairness in corporate compensation practices, in a decision rendered last year regarding NLPC’s shareholder proposal at Disney. NLPC sponsored similar proposals last year at Johnson & Johnson and PepsiCo. You can read NLPC’s shareholder proposal for Visa at its website. Last year Chesser also composed commentaries for the New York Post and Real Clear Markets that further explained the proposals and their necessity. Founded in 1991, NLPC promotes ethics in public life and government accountability through research, investigation, education, and legal action. ### For more information or to schedule an interview with Paul Chesser, contact Dan Rene at 202-329-8357 or drene@nlpc.org. Please visit http://www.nlpc.org. Founded in 1991, the National Legal and Policy Center promotes ethics in public life through research, investigation, education and legal action. Contact Details National Legal and Policy Center Dan Rene +1 202-329-8357 drene@nlpc.org Company Website http://www.nlpc.org

January 28, 2025 09:00 AM Eastern Standard Time

Article thumbnail News Release

Deaf Organizations Fund Unveils 2025 Grantees Resourcing Deaf Communities

Communication Service for the Deaf

Deaf Organizations Fund (DOF) proudly announces the selection of four organizations receiving unrestricted grants this month to address the diverse needs of their deaf communities through 2025: Atomic Hands, Deaf Defy, Inc., DEAFinitely, Inc., and The Black Deaf Project. The $100K distributed among these organizations will support accessible educational and multicultural resources, break down healthcare barriers, and expand opportunities for DeafBlind youth, giving grantees the flexibility to direct funding where it is most needed. “As a small, Deaf-run nonprofit, it means so much to see a funder like this one specifically targeting deaf-centric organizations,” said Zaineb Abdulla, Founder of Deaf Defy, Inc. “I love the inclusion of using American Sign Language in all engagement with DOF.” DOF’s second unrestricted Impact Grant for Deaf Organizations received a record-breaking 84 applications from deaf-centric organizations and programs. In alignment with participatory grantmaking, a community-led grant review committee shaped the decision-making process. They evaluated all eligible applications and supported DOF in making the final award decisions. “Our trust-based approach to grantmaking has been met with incredible support, and we’re excited to continue working alongside organizations that are igniting meaningful change in our deaf communities,” said Sasha Ponappa, Executive Director of DOF. "We are also deeply grateful for ongoing support from our donors and partners, whose contributions ensure DOF's ability to fund and resource deaf organizations." As DOF enters its sixth funding cycle, the team is also focused on expanding resources beyond grant dollars. This support includes grantee coaching, technical assistance, the development of an accessible training program and community hub for deaf organization leaders, and advocacy for disability justice within the philanthropic sector. To learn more about DOF’s impact and the work of its grantee organizations, interested parties are invited to view the newly released Social Impact Report. Funders and supporters who wish to contribute to DOF’s mission are encouraged to reach out directly. About Deaf Organizations Fund (DOF): DOF was established in 2021 by its fiscal sponsor, Communication Service for the Deaf, offering fully accessible grants and resources to deaf-centric organizations and programs based in the United States. To date, DOF has distributed nearly $500K in grant funds among 27 deaf-centric organizations and programs. Contact Details Avi Haimowitz, Director of Development dof@deaforganizationsfund.org Company Website https://deaforganizationsfund.org/

January 27, 2025 11:33 AM Eastern Standard Time

Article thumbnail News Release

Groundwork BioAg and Sustainable Travel International Partner to Offer Carbon Dioxide Removal Credits for Tourism

Groundwork BioAg

Groundwork BioAg ®, the world’s largest producer of mycorrhizal inoculants, announced a new partnership with Sustainable Travel International, a global leader in sustainable tourism solutions, to offer travelers and businesses access to premium carbon dioxide removal (CDR) credits, based on the application of mycorrhizal fungi in cropland. Mycorrhizal inoculants are applied in agricultural soils to improve crop yields, save fertilizer, reduce plant stress, and improve soil health – but at the same time, these microbial products act as a natural pathway to permanently sequester carbon. This partnership aligns with Sustainable Travel International’s mission to provide programs that help travelers, businesses and destinations protect the environment, preserve cultural heritage and promote economic development. Groundwork BioAg's Rootella Carbon™ program offers high-integrity, high-volume, durable carbon credits that are independently certified and approved, providing a reliable solution for organizations seeking to meet their net-zero pledges responsibly. "By adding Rootella Carbon to our Climate Impact Portfolio, we reaffirm our commitment to promote holistic environmental stewardship so our members can visit – and protect – the places they love,” said Paloma Zapata, CEO of Sustainable Travel International. “This innovative, nature-based solution aligns with our mission to help the travel industry address its carbon liability while directly improving soil health around the world.” Sustainable Travel International’s Climate Impact Portfolio includes a wide variety of projects in different locations that generate carbon credits as they reduce or remove emissions. The portfolio includes a mix of high-quality forestry, clean/efficient energy, blue/teal carbon, and innovative climate tech projects. The demand for high-quality carbon credits is growing rapidly, with two-thirds of the world's largest companies with net-zero targets using carbon offsets to help meet their climate goals. Rootella Carbon credits stand out among durable CDR credits as a scalable solution that not only sequesters carbon in the soil but also improves crop yields, reduces chemical fertilizer use, mitigates plant stress and supports regenerative agricultural practices. Dan Grotsky, co-founder and chief growth officer of Groundwork BioAg, said, "This collaboration not only validates the effectiveness of our Rootella Carbon program but also demonstrates the travel industry's commitment to sustainable practices. Together, we are paving the way for significant carbon sequestration by enabling travelers and rewarding farmers around the world – while contributing to a healthier planet." Rooted in Groundwork BioAg’s history of helping growers improve the productivity and profitability of their farms, this partnership now gives travelers the opportunity to directly support farmers for their land stewardship while reducing their own carbon footprint. Currently under validation within the Verra VM0042 v2.0 protocol, Rootella Carbon offers farmers the opportunity to earn up to 70% of net proceeds from carbon credit sales, making it an attractive option for growers looking to diversify their income streams. This innovative approach unlocks compensation for regenerative growers who would otherwise be ineligible for carbon credits, while incentivizing conventional farmers to adopt regenerative practices. For more information about Groundwork BioAg and the Rootella Carbon program, visit GroundworkBioAg.com. About Groundwork BioAg Groundwork BioAg, a leading bioagriculture company, produces cost-effective mycorrhizal inoculants at scale to tackle food insecurity and climate change. Groundwork BioAg’s nature-based carbon dioxide removal solution leverages mycorrhizae as carbon’s main pathway into the soil and is supercharging permanent carbon sequestration on millions of hectares of commercial and regenerative farms globally. We envision the world’s cropland regenerating with mycorrhizae and every farmer benefiting from higher yields, healthier soils, fertilizer reduction, and verifiable, premium carbon credit revenue – without altering cultivation practices. Nature’s most potent carbon removal solution is now in every farmer’s hands. For more information, visit groundworkbioag.com or groundworkbioag.com/rootella-carbon. Contact Details AgTech PR for Groundwork BioAg Jennifer Goldston jennifer@agtechpr.com Company Website https://www.groundworkbioag.com

January 22, 2025 10:32 AM Central Standard Time

Article thumbnail News Release

Cortland Biomedical Secures FDA Registration, Expanding Role as a Trusted Contract Manufacturer for Medical Device OEMs

Cortland Biomedical

Cortland Biomedical, a full-service biomedical textile product development partner that provides access to a full spectrum of global engineering, design, and manufacturing capabilities, is proud to announce its FDA registration, marking a significant milestone in the company’s evolution. This new designation positions Cortland Biomedical as a full-service contract manufacturer and reinforces the company’s unwavering commitment to delivering the highest standards of quality, compliance, and service to its medical device customers. As an FDA-registered contract manufacturer, Cortland Biomedical will better support its clients in highly regulated markets, particularly in the orthopedic sector, where precision and reliability are critical. The FDA registration, partnered with ISO 13486:2016 compliance, ensures that Cortland Biomedical operates under a robust Quality Management System (QMS) that meets stringent regulatory requirements, offering its customers peace of mind in the safety and performance of their devices. “FDA registration is a game-changer for Cortland Biomedical and our customers,” said Tara Yunkunis, Senior Business Development Manager, Cortland Biomedical. “This milestone underscores our dedication to maintaining world-class quality systems and compliance practices. As a contract manufacturer, we can now take a more active role in helping our customers bring innovative medical devices to market faster and with greater confidence.” With extensive expertise in the design and production of advanced biomedical textiles, Cortland Biomedical specializes in creating tailored solutions for a range of applications, including orthopedics, sports medicine, cardiovascular, robotic surgery, general surgery, and others. This expanded capability allows it to now partner with OEMs from initial concept through full-scale manufacturing, providing a seamless, forward-integrated approach to medical device development. For more information about Cortland Biomedical and its expanded capabilities as an FDA-registered contract manufacturer, visit cortlandbiomedical.com or come see the team in booth 2127 at the upcoming MD&M West show in Anaheim, CA. Cortland Biomedical custom designs and manufactures high-performance biomedical textile structures leveraging years of experience in medical textile engineering methods including knitting, braiding and weaving. Its thoughtful design concepts challenge the status quo. Cortland Biomedical's unique combination of advanced equipment and technology, a seasoned medical textile-specific engineering team, and first-rate R&D capabilities allows it to tackle customers' complex challenges with the innovation and agility expected in the medical device industry. Learn more at cortlandbiomedical.com. Contact Details Jordan Bouclin, SVM Public Relations +1 401-490-9700 Jordan.bouclin@svmpr.com Company Website https://www.cortlandbiomedical.com/

January 22, 2025 10:00 AM Eastern Standard Time

Article thumbnail News Release

How Monogram’s (NASDAQ: MGRM) Dynamic Approach To Robotics Could Help Reshape the Future Of Orthopedics

Benzinga

By Meg Flippin Benzinga Robots are becoming increasingly more common in the operating room, but just how automated are they? Monogram Orthopedics Inc. (NASDAQ: MGRM) would argue we have a long way to go before the full potential of robotic technology is fully tapped. The proliferation of robotics and increasing utilization is, at this point, likely a foregone conclusion. After all, some estimates predict that 50% of all knee procedures will be robotic by 2027, up from 11% in 2019. Yet despite the proliferation of AI and fully autonomous robotics in nearly every aspect of daily life, the surgical equipment currently in use for common orthopedic procedures is still reliant on surgeon skill. Monogram’s mBôs robotic technology aims to increase automation and reduce reliance on user skills. As a pioneer in autonomous saw-based cutting, the company has applied decades of robotics experience to amass an extensive portfolio of innovation, including some 23 patent applications in process. The majority of procedures done today combine manual surgery with robotics. The process can still rely heavily on surgeon skill to safely execute the surgery. Monogram’s mBôs aims to minimize direct surgeon contact with the robot mounted tools and hopes to provide surgeons a more autonomous platform for precise surgical bone cuts based on preoperative planning. Monogram’s autonomous robotics platform captured the attention of investment bank Roth Capital Partners, which recently initiated coverage of the company, noting mBôs simplifies surgery as a likely direct challenge to the dominant players in the space. “While orthopedic surgeons remain characteristically conservative, the clinical case for robotics technology is building, and robotics are changing market dynamics,” according to an analyst report compiled by Roth Managing Director Jason Wittes. “We anticipate adoption surpassing 50% over the next five years, and thus see significant strategic value in emerging robotics platforms such as MGRM's mBôs that can challenge MAKO’s dominance.” In addition, Monogram reports its technology pipeline is robust. It plans to introduce mVision in the future, which could enable faster registration and further optimize surgical time compared to competitors. Combination Of Advanced Technologies To Deliver Results Monogram leverages AI and robotics to develop state-of-the-art robots that can assist surgeons with knee reconstruction and, in the future, other procedures like hips, shoulders, ankles and spine. Monogram’s robotic systems aim for precise virtual assessment of laxity values to determine the potential clinical impact of planned resections. Its technology enables surgeons to place implants virtually before cutting to assess the impact of various resections on knee laxity with a target to achieve submillimeter bone cuts. These tools could dramatically simplify the complexity of joint reconstruction in the future. Monogram hopes the mBôs automation could increase throughput and hopes to reduce clinical risk with a planned clinical study to validate. The goal is for the robot to be easy to use and to lower the learning curve for surgeons. With accurate robotics, precision machine cuts can help enable the use of press-fit implants, eliminating the need for cement. Unlike traditional implants, press-fit implants rely on the patient’s bone to hold the implant in place instead of relying on cement. Natural biologic fixation could reduce the risk of the implant becoming loose for younger active patients as the cement breaks down over time. Showing Off The Tech At HQ Monogram’s unique approach to robotics was on display during an analyst meeting and demo day held in 2024 at the company’s cadaver lab and headquarters in Austin, Texas. Monogram executives – including CEO Ben Sexson, Founder and Chief Medical Officer Dr. Douglas Unis, Chief Technology Officer Dr. Kamran Shamaei and Chief Financial Officer Noel Knape – were on hand along with other senior management team members to provide an overview of the company's progress in combining advanced machine vision, AI and next-generation robotics to improve surgeries and patient outcomes. “We were extremely impressed with the management team, including founder Doug Unis, and the successful product Demonstration of the mBôs Precision Robotic Surgical System in a world-class cadaver lab,” said Dallas Salazar, Doctor Group investor. “The hands-free, fully active system demonstrated to us the ease of use and simplicity that was operated by the founder’s 11-year-old daughter giving more confidence of commercialization and acceptance in the orthopedic robotics community once approved. We believe there is clearly a disruptor in this space that is now bringing a product solution architecture to enable patient-optimized orthopedic implants at scale utilizing artificial intelligence and next-generation robotics.” Market Direction The company believes that the future of the market for robotics is bright. With continued robotic adoption driven by patient outcomes and healthcare providers, it believes robotics are likely to become increasingly autonomous. Given the advancements made in AI and robotics, the systems in place today may still be relatively constrained by a reliance on the precision of individual surgeons. The full potential of robotics could be realized across myriad industries. With the anticipated growth in surgical procedures and critical patient and healthcare business outcomes at stake, coupled with a declining number of orthopedic surgeons, automation could be an answer to the growing demand. Monogram aims to introduce an approach to enabling true automated robotic precision that has the potential to transform the way surgeons around the world perform knee replacements and other orthopedic procedures. Featured photo by SOMKID THONGDEE on Shutterstock. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

January 22, 2025 08:45 AM Eastern Standard Time

Image
Article thumbnail News Release

Salignostics Advances Saliva-Based HIV Testing with Successful Clinical Trial in Ethiopia

Salignostics

Salignostics, a leader in saliva-based diagnostic innovation, proudly announces the successful completion of a clinical trial in Ethiopia for its groundbreaking saliva-based HIV rapid test. This major milestone brings Salignostics closer to providing a transformative solution for HIV testing, particularly in areas with limited access to healthcare infrastructure. The trial, conducted in November 2024, evaluated 50 saliva samples from individuals diagnosed with HIV alongside 50 samples from healthy participants. The results demonstrated exceptional accuracy, with sensitivity exceeding 90% and specificity surpassing 98%. These findings underscore the reliability of saliva as a diagnostic medium and highlight its potential to address critical healthcare challenges worldwide. Accurate, accessible HIV testing is vital for early detection and treatment, especially in underserved regions. Salignostics’ saliva-based test eliminates the need for blood draws and specialized equipment, offering a cost-effective and non-invasive alternative that can be deployed in homes, clinics, or community health settings. This innovation not only reduces barriers to testing but also empowers individuals to take control of their health with privacy and convenience. “This successful trial highlights the value of saliva as a diagnostic medium,” said Dr. Guy Krief, Co-founder and Deputy CEO of Salignostics. “By leveraging our technology, we aim to complement existing HIV testing methods and provide a reliable, accessible solution that meets the needs of diverse communities worldwide.” The global HIV diagnostics market is rapidly expanding, driven by increasing demand for decentralized and user-friendly solutions. The market is projected to reach $3.88 billion by 2021, with forecasts of further growth to over $7 billion by 2034 at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2034. Building on its success with saliva-based diagnostics, Salignostics continues to expand its portfolio. The company has a proven track record, including CE, UKCA, and TGA certifications for its Salistick pregnancy test, which has achieved over 500,000 units sold and ordered across markets such as the UK and Israel. Salignostics’ development pipeline also includes applications for oral cancer, respiratory conditions, and sexually transmitted infections, further demonstrating the versatility of saliva as a diagnostic tool. For Salignostics, the successful Ethiopian trial is a significant step forward in transforming global healthcare. By providing accurate and accessible HIV testing, the company is addressing critical gaps in public health while reinforcing its commitment to innovation and quality in diagnostics. About Salignostics Founded in 2017 in Jerusalem, Salignostics is a global leader in saliva-based diagnostics. The company’s proprietary technology has been successfully commercialized, with its Salistick pregnancy test achieving over 500,000 units sold and ordered in markets such as the UK and Israel. Now approved by CE, UKCA, and TGA, Salignostics is actively expanding its portfolio of innovative, user-friendly diagnostic solutions. For more information about Salignostics and its groundbreaking saliva-based diagnostics, visit www.salignostics.com Founded in 2017 in Jerusalem, Salignostics is a global leader in saliva-based diagnostics. The company's proprietary technology has been successfully commercialized, with its Salistick pregnancy test achieving over 500,000 units sold and ordered in markets such as the UK and Israel. Now approved by CE, UKCA, and TGA, Salignostics is actively expanding its portfolio of innovative, user-friendly diagnostic solutions. For more information about Salignostics and its groundbreaking saliva-based diagnostics, visit www.salignostics.com Contact Details Salignostics Guy Krief | Co-founder and Deputy CEO, Salignostics guykrief@salignostics.com Company Website https://www.salignostics.com/

January 21, 2025 05:15 PM Eastern Standard Time

Article thumbnail News Release

Flash Earns HITRUST Certification, a First in Parking Technology

Flash

Flash, the leading AI-powered parking technology provider, today announced it has achieved HITRUST Certification for its PARCS and Valet solutions, the first and only parking technology provider to earn the distinction. The achievement confirms Flash’s data security practices meet the highest standards trusted by 81 percent of U.S. hospitals and health systems. Flash's HITRUST-certified PARCS and Valet solutions align its security frameworks with those of its healthcare clients and reduce their implementation complexity and risk. The certification also gives assurance to patients, visitors, physicians and staff that their information is safe from the moment they enter the parking facility. “We have a track record of setting new standards in parking," said Flash CEO Dan Sharplin. “Our focus on reimagining the parking experience calls for putting security front and center, within and beyond healthcare. We’re also committed to a great experience for operators and owners, and this certification allows us to carry the technical burden of compliance on their behalf.” Flash PARCS and Valet solutions have earned the trust of the country’s largest medical district and from healthcare systems in major metros nationwide, including Atlanta, Boston, Chicago, Denver, Houston, New York City, Orange County, Phoenix, Pittsburgh and San Diego. Flash’s industry-leading parking technology has also earned designation as a Level 1 Service Provider by the Payment Card Industry (PCI) Data Security Standards (DSS), which it has maintained for 11 consecutive years. Its cloud-based platform can process over 500 million transactions yearly in a secure environment that limits the risk of data loss, disruption, or corruption. Operating entirely in the cloud also allows Flash to manage compliance for operators and owners, pushing security updates and routine system checks required by PCI and HITRUST standards over the air, which become operational within minutes. About Flash Flash is a pioneering technology company bringing seamless parking and EV charging experiences to drivers through a first-of-its-kind digital ecosystem. Flash’s platform connects reservable parking and charging in the apps drivers use daily with garage, surface lot, event, and valet parking locations—connected and controlled via a cloud-based operating system with unrivaled intelligence. Customer-obsessed brands partner with Flash to deliver digital, easy-to-use, reliable, and increasingly frictionless experiences to drivers eager to pay for a solution that eliminates wasted time, excess emissions, and stress. The solution has arrived. Visit www.flashparking.com to learn more. Contact Details Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website https://www.flashparking.com/

January 21, 2025 10:00 AM Central Standard Time

Article thumbnail News Release

IntusCare Announces Marcus Whitney as New Board Member, Strengthening Leadership and Expertise in Healthcare Innovation

IntusCare

IntusCare, a technology leader in the PACE market, today announced the addition of Marcus Whitney, founder and managing partner of Jumpstart Health Investors (JHI), to its Board of Directors. A healthcare venture capitalist, author, and thought leader, Whitney brings his extensive expertise in healthcare innovation and strategic investments and marks a significant step forward in the company’s commitment to improving healthcare outcomes for older adults through technology and services. As a founding partner of JHI, an early-stage healthcare venture capital firm, Whitney has been instrumental in driving investments that focus on high-impact healthcare solutions that address healthcare disparities and push for equitable access to care. Whitney’s approach emphasizes not use innovation but inclusivity – values that align with IntusCare’s mission to enhance PACE and value-based care (VBC) organizations. Whitney joins the board at IntusCare as the company continues to expand its technology platform, recently announcing a new EMR and practice management solution, CareHub, along with a risk adjustment system, IRIS, both uniquely designed specifically for PACE and VBC organizations. “Marcus’s visionary approach and expertise in healthcare innovation will enhance our approach at IntusCare as we continue to look for ways our technology and services will empower the healthcare providers we support,” said Robbie Felton, CEO at IntusCare. “His expertise will be invaluable as we continue to develop technology that enables healthcare providers to deliver more effective, compassionate care to underserved elderly populations.” “I am honored to serve on the board for IntusCare. The IntusCare team is leading the industry in redefining care for a critical population,” said Whitney. “I look forward to contributing to their mission and the bright future ahead.” In addition to his role at JHI, Whitney is a best-selling author of “Create and Orchestrate,” about claiming your creative power through entrepreneurship. Whitney is an Aspen Health Innovators Fellow and serves on multiple boards that support healthcare and the arts; this includes the Healthcare Financial Management Association National Board. He is also co-founder and minority owner of the Major League Soccer team, Nashville Soccer Club. Whitney competes in Jiu Jitsu as an International Brazilian Jiu-Jitsu Federation (IBJJF) World Master Champion. For more information about IntusCare’s software and services or to schedule a demo or consultation, reach out through IntusCare’s website. About IntusCare ‍ IntusCare develops innovative predictive analytics platforms aimed at improving geriatric care outcomes. Founded in 2019 by Brown University undergraduate students, IntusCare empowers geriatric care providers to deliver more effective patient management and treatment for dual-eligible seniors – some of the most socially vulnerable and clinically complex individuals in the U.S. healthcare system. Visit our website to learn more intuscare.com. Contact Details SVM PR & Marketing Alison Matthiessen +1 401-490-9700 intuscare@svmpr.com Company Website https://intuscare.com/

January 21, 2025 10:00 AM Eastern Standard Time

12345 ... 306